Abiomed Receives Reimbursement Approval for Impella in The Netherlands

Abiomed Receives Reimbursement Approval for Impella in The Netherlands

DANVERS, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD),
a leading provider of breakthrough heart support technologies, today announced
that the Netherlands has approved new reimbursement coding and payment for the
Impella product. The new coding allows for hospitals to receive funding for
the use of the Impella technology in a broad set of clinical indications of
heart disease through the process known as Diagnosis Treatment Combinations
(Diagnose Behandeling Combinaties; DBCs), similar to the Medicare
Diagnosis-Related Group (DRG) system in the United States.

New reimbursement is a significant milestone for the recognition of Impella as
a required therapy for treatment of heart disease in the European hospital
setting. The Netherlands has also been a leader in early clinical and cost
effectiveness research of the Impella technology under the leadership of Dr.
Jose Henriques at the Amsterdam Medical Center.

"We are encouraged that the Netherlands now provides reimbursement for
Impella," said Michael R. Minogue, Chairman, President and Chief Executive
Officer of Abiomed. "The World Health Organization ranks the Netherlands as
one of the top healthcare systems globally, based upon measurements of the
overall level and distribution of health, responsiveness, and financial
contribution to healthcare services."


Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of
medical devices that provide circulatory support.Our products are designed to
enable the heart to rest by improving blood flow and/or performing the pumping
of the heart. For additional information please visit: www.abiomed.com


This release contains forward-looking statements, including statements
regarding development of Abiomed's existing and new products, the Company's
progress toward commercial growth, and future opportunities and expected
regulatory approvals. The Company's actual results may differ materially from
those anticipated in these forward-looking statements based upon a number of
factors, including uncertainties associated with development, testing and
related regulatory approvals, including the potential for future losses,
complex manufacturing, high quality requirements, dependence on limited
sources of supply, competition, technological change, government regulation,
litigation matters, future capital needs and uncertainty of additional
financing, and other risks and challenges detailed in the Company's filings
with the Securities and Exchange Commission, including the most recently filed
Annual Report on Form 10-K and quarterly report on Form 10-Q. Readers are
cautioned not to place undue reliance on any forward-looking statements, which
speak only as of the date of this release. The Company undertakes no
obligation to publicly release the results of any revisions to these
forward-looking statements that may be made to reflect events or circumstances
that occur after the date of this release or to reflect the occurrence of
unanticipated events.

CONTACT: For further information please contact:
         Susie Lisa, CFA
         Senior Director, Investor Relations and Corporate Development
         Aimee Genzler
         Corporate Communications Manager

Abiomed Logo
Press spacebar to pause and continue. Press esc to stop.